News
Joint statement on Modalis
Joint Statement on Modalis Therapeutics’ MDL-101 Programfor LAMA2-Related DystrophyCure CMD, Voor Sara, Modalis Therapeutics June 2026 In light of…
Research updates
-
![]()
News
-
![]()
News
Extension of natural history study: an important step toward better care and clinical trials
The Prinses Beatrix Spierfonds, Stichting Voor Sara, CureCMD and Giving Strength are continuing their collaboration with Radboudumc by extending and…
-
![]()
Research updates
An important new step toward a treatment for LAMA2-MD thanks to Modalis
Modalis Therapeutics, the biotechnology company developing novel gene-based therapies for the rare inherited muscle disease LAMA2-MD, has recently published an…
-
![]()
Research updates
Working together for hope: An international step toward a treatment for LAMA2-RD
The Dutch foundation Voor Sara is investing over €45,000 in a promising research project led by Professor Markus Rüegg at…
-
![]()
Research updates
LAMA2 France supports two new research projects with funding
The French patient association LAMA2 France, dedicated to people affected by LAMA2-related dystrophy (LAMA2-RD), is pleased to announce that they…
-
![]()
Research updates
Postdoc Boris Shneyer provides an update on his research into LAMA2-RD
Postdoctoral researcher Boris Shneyer shares the latest developments in his research on LAMA2-RD, the progress made so far, and the…
The driving forces behind Lama2.com
Bekijk alle partners
